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Abstract The prevalence of type 2 diabetes mellitus
(T2DM) and its major risk factor, obesity, has reached
epidemic proportions in Western society. How obesity
leads to insulin resistance and subsequent T2DM is
incompletely understood. It has been established that
insulin can redirect blood flow in skeletal muscle from
non-nutritive to nutritive capillary networks, without
increasing total blood flow. This results in a net in-
crease of the overall number of perfused nutritive cap-
illary networks and thereby increases insulin-mediated
glucose uptake by skeletal muscle. This process, re-
ferred to as functional (nutritive) capillary recruitment,
has been shown to be endothelium-dependent and to
require activation of the phosphatidylinositol-kinase
(PI3K) pathway in the endothelial cell. Several studies
have demonstrated that these processes are impaired in
states of microvascular dysfunction. In obesity, changes
in several adipokines are likely candidates to influence
insulin signaling pathways in endothelial cells, thereby
causing microvascular dysfunction. Microvascular dys-
function, in turn, impairs the timely access of glucose
and insulin to their target tissues, and may therefore be
an additional cause of insulin resistance. Thus, micro-
vascular dysfunction may be a key feature in the devel-
opment of obesity-related insulin resistance. In the
present review, we will discuss the evidence for this
emerging role for the microcirculation as a possible link
between obesity and insulin resistance.
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1 Introduction
The prevalence of obesity is increasing worldwide and has
reached epidemic proportions in Western society [1]. Central
obesity and a sedentary lifestyle are main causes of insulin
resistance and type 2 diabetes mellitus (T2DM) [2, 3]. The
increases in their prevalence results in an increased prevalence
of T2DM, with an estimated 285 million people with T2DM
worldwide and a further seven million people developing
T2DM each year [4]. However, how obesity leads to T2DM
is incompletely understood, and further insight into this path-
ophysiology may contribute to more precise risk assessment
for the development of T2DM and additionally to new treat-
ment targets for prevention of T2DM.
Microvascular dysfunction may be both cause and
consequence of T2DM. On the one hand, it is generally
accepted that T2DM causes microvascular dysfunction
and microvascular complications such as nephropathy
and retinopathy [5]. On the other hand, microvascular
dysfunction has been identified as an antecedent of
T2DM [5]. In addition, we [6–8] and others [9, 10]
have demonstrated that microvascular dysfunction is
impaired in (central) obesity, and obesity has been sug-
gested as a primary cause of microvascular dysfunction
[11]. Therefore, microvascular dysfunction may be an
intermediate step linking central obesity to insulin resis-
tance and T2DM [11–14].
In the present review, we will discuss the role of micro-
vascular dysfunction as a key feature in the development of
obesity-related insulin resistance and T2DM.
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2 Microcirculation: definition, function, and assessment
The microcirculation can be defined anatomically, i.e. as
vessels less than 150 μm in diameter, including all capillar-
ies and venules and small arterioles [15]. However, this
definition excludes larger arterioles with a diameter above
150 μm, which may be important to microcirculatory func-
tion [15]. An alternative definition is based on arterial/arte-
riolar vessel physiology, and includes all vessels that
respond to increased pressure by a myogenic reduction in
lumen diameter. Such a definition also includes the larger
arterioles in the microcirculation in addition to capillaries
and venules [11, 15, 16].
The microcirculation has three essential functions which
serve to regulate whole body and tissue metabolism, and
blood pressure [12, 13]: 1) regulation of the exchange of
nutrients, oxygen, and hormones; 2) avoidance of large
fluctuations in hydrostatic pressure at the capillary level;
and 3) determining the overall peripheral resistance, since
the quantitatively most substantial drop in hydrostatic pres-
sure occurs at the level of the microcirculation [15]. Micro-
vascular dysfunction is defined as an impairment in one or
more of these functions.
Currently, several types of estimates of microvascular
(endothelial or smooth muscle cell) function are available
[17]. First, assessment of microvascular function in specific
microvascular beds is frequently used, such as in 1) skin (by
capillaroscopy and laser-Doppler fluxmetry); 2) muscle (by
plethysmography and contrast-enhanced ultrasonography);
3) conjunctival bed (by intravital microscopy) and 4) retina
(by photography). Responses can be studied in the basal
state and after applying a stimulus, such as reactive hyper-
emia, heating, or local or systemic administration of
endothelium-(in)dependent vasoactive agents such acetyl-
choline and sodium nitroprusside, with lower responses in
general reflecting microvascular dysfunction [18–20]. In
addition, in the retinal microvasculature (as evaluated by
retinal photography) [21–24] venular dilation and arteriolar
narrowing have been associated with, and may be markers
of, endothelial dysfunction [25]. Moreover, responses of the
retinal microvasculature can be studied after applying a
flicker-light stimulus, with lower responses thought to re-
flect endothelial dysfunction [26]. Second, microvascular
function can be assessed with the use of biomarkers. Thus,
measurement of plasma levels of endothelium-derived reg-
ulatory proteins (e.g. soluble E-selectin (sE-selectin), solu-
ble intercellular adhesion molecule 1 (sICAM-1), soluble
vascular adhesion molecule 1 (sVCAM-1), and von Wille-
brand factor (vWF) [27]) is often used. Increased levels of
these markers are thought to reflect endothelial permeability
to leucocytes (i.e. sE-selectin, sICAM-1, and sVCAM-1)
[27–30], and prothrombotic and procoagulant activity (i.e.
vWF) [27, 29, 30]. Note that the microvascular endothelium
is the most important determinant of these plasma markers
of endothelial dysfunction [27, 31–33], because of its large
surface area and production capacity (i.e. the microvascula-
ture covers 98 % of the total vascular surface area [34]). For
these reasons, it is plausible to assume that higher circulat-
ing concentrations of these markers reflect microvascular
endothelial dysfunction. Another biomarker of microvascu-
lar function is urinary albumin excretion or microalbuminu-
ria, which is thought to reflect a generalized increase in
endothelial permeability [27], and is frequently used as a
marker of general endothelial dysfunction [27, 29, 30,
35–37]. This concept is derived from data showing that
microalbuminuria is associated with a greater transcapillary
escape rate of albumin, i.e. with greater microvascular per-
meability [27] and from data showing that microalbuminuria
is strongly associated with risk of cardiovascular disease,
that this association cannot be explained by conventional
risk factors, and that changes in microalbuminuria are paral-
leled by changes in cardiovascular risk (reviewed elsewhere
[38]). In general, assessment of microvascular function
in specific vascular beds is technically demanding and
time-consuming, and is thus mostly used in relatively
small-scale, experimental studies, whereas the use of
biomarkers is especially suitable for large-scale observa-
tional studies.
3 Microvascular dysfunction: a cause of insulin
resistance
Insulin resistance is typically defined as decreased sensitiv-
ity and/or responsiveness to the metabolic actions of insulin,
which results in impaired glucose disposal [11, 13, 39, 40].
In muscle cells, activation of the phosphatidylinositol-
kinase (PI3K) pathway leads to translocation of glucose
transporter-4 (GLUT-4) to the cell membrane, which acti-
vates the downstream pathways of glucose metabolism [11,
13, 39–41]. The translocation of GLUT-4 is believed to be
the rate-limiting step for insulin-mediated glucose uptake in
muscle [41, 42]. Several studies demonstrated that inappro-
priate fat accumulation in muscle cells or the release of
inflammatory cytokines by fat cells may affect this pathway
[41, 43, 44]. This process is referred to as metabolic insulin
resistance, and is widely accepted to precede the develop-
ment of T2DM [45]. Nevertheless, most studies investigat-
ing metabolic insulin resistance examined individuals with
long-standing T2DM [46]. These studies demonstrated that
there are indeed defects in the insulin-signaling pathway in
muscle cells in the diabetic state [18, 47]. However, an
important and necessary step preceding translocation of
GLUT-4 is the perfusion of the microvasculature within
the skeletal muscle in order to deliver insulin and glucose
to the muscle cells.
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Since the 1990s, there has been an increasing interest in
this precellular step, and it has become clear that the deliv-
ery of insulin and glucose to muscle tissue is regulated by
insulin itself via direct effects on microvascular function that
require activation of the insulin receptor on endothelial cells
[11, 40]. Baron and colleagues [48] first reported that insulin
increases total blood flow in skeletal muscle, which is
paralleled by an increase in insulin-mediated glucose uptake
[48, 49]. Although some studies have confirmed this vascu-
lar action of insulin [50, 51], most studies observed only
insulin-mediated increases in total limb blood flow after
using supra-physiological doses of insulin or after several
hours of delay when physiological concentrations were used
[52–54]. Therefore, the physiological importance of insu-
lin’s ability to increase total blood flow remains controver-
sial [11, 18, 53]. However, besides these actions on
resistance vessels, insulin can redirect blood flow in skeletal
muscle from non-nutritive to nutritive capillary networks,
without increasing total blood flow. This results in a net
increase of the overall number of perfused nutritive capillary
networks [11], and thereby increases insulin-mediated glu-
cose uptake by skeletal muscle [40, 52]. This process is
referred to as functional (nutritive) capillary recruitment.
Such capillary recruitment requires physiological concen-
trations of insulin and has a time course that accords well
with the time course for insulin-mediated glucose uptake in
skeletal muscle [39, 53, 55]. In addition, this process has
been shown to be endothelium-dependent, requiring activa-
tion of the PI3K pathway in the endothelial cell [39], in-
cluding the insulin receptor, insulin receptor substrate 1
(IRS-1), insulin receptor substrate 2 (IRS-2) [56],
phosphoinositide-dependent kinase 1 (PDK-1), and protein
kinase B (Akt) [39, 41] (Fig. 1). In contrast to muscle cells,
this activation does not result in translocation of GLUT-4 to
the cell surface, but in the production of NO due to in-
creased endothelial NO synthase (eNOS) activity [39]
(Fig. 1). Consequently, insulin-induced stimulation of endo-
thelial cells leads to increased NO production, which stim-
ulates capillary recruitment [39] and transendothelial
transport of insulin [57]. In addition, however, insulin also
has vasoconstrictor effects through the production of
endothelin-1 (ET-1) through stimulation of the intracellular
MAP kinase signaling (MAPK) pathway and extracellular
signal-regulated kinase-1/2 (ERK-1/2) (Fig. 1) [39]. In
physiological conditions, when insulin binds to the insulin
or insulin-like growth factor receptor on endothelial cells
[58], the net result usually favors NO production [11] and
thus vasodilatation and capillary recruitment.
There now is substantial evidence, derived from both ani-
mal experiments and observations in humans, that this path-
way is an important determinant of insulin-mediated glucose
uptake in muscle. Thus, Clark and colleagues [59] were the
first to report insulin-mediated capillary recruitment in skeletal
muscle of the rat hind limb. In subsequent in vivo rat studies,
the effect of insulin on capillary perfusion was confirmed [54,
60, 61]. In human muscle, it was established that insulin
increased microvascular blood volume [62, 63]. In addition,
hyperinsulinemia was shown to enhance skin post-occlusive
capillary recruitment and microvascular vasomotion [64, 65].
Moreover, capillary recruitment and acetylcholine-
mediated vasodilatation of both skin and resistance ar-
teries were strongly associated with insulin sensitivity
[66–70] In further support of the physiological impor-
tance of insulin-mediated capillary recruitment, several
studies have demonstrated that insulin-mediated capil-
lary recruitment contributes to glucose disposal in skel-
etal muscle [6, 52, 55, 56, 63, 71, 72]. In subsequent
studies, it was established that approximately 40 % of
insulin-mediated glucose uptake by skeletal muscle can
be attributed to capillary recruitment [55, 73, 74]. In
Fig. 1 When insulin binds on the insulin receptor of endothelial cells,
the PI3K and MAPK pathways in the endothelial cell are activated.
These activations lead to the production of NO and ET-1, resulting in
vasodilatation and vasoconstriction respectively. Normally, the net
result usually favors NO production, resulting in a redirection of blood
flow in skeletal muscle from non-nutritive capillaries to nutritive
capillaries, thereby increasing insulin-mediated glucose uptake by
skeletal muscle. In obesity, there is an increase in several circulating
adipose tissue-derived factors, in particular FFA and TNF-α, whereas
the anti-inflammatory adipokine adiponectin is decreased. FFA and
TNF-α affect the insulin signaling pathway in endothelial cells by
the activation of PKC θ and JNK respectively. In addition, decreased
adiponectin levels decrease AMPK phosphorylation. Accordingly,
these endocrine factors are likely candidates to influence insulin sig-
naling pathways (i.e. decreased PI3K activation and increased ERK-1/
2 activation) in endothelial cells, thereby impairing insulin-mediated
vasodilatation and capillary recruitment, and thus skeletal muscle glu-
cose uptake. black arrows—stimulation; red arrows—inhibition; IRS-
1/2—insulin receptor substrate 1/2; PI3K—phosphatidylinositol-ki-
nase-dependent; Akt—protein kinase B; eNOS—endothelial nitric ox-
ide synthase; NO—nitric oxide; ERK-1/2—extracellular signal-
regulated kinase-1/2; ET-1—endothelin-1; FFA—free fatty acids;
TNF-α—tumor necrosis factor-α; JNK—intracellular enzyme c-Jun
N-terminal kinase; PKC θ—protein kinase C; AMPK—5′ adenosine
monophosphate-activated protein kinase
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pathophysiological conditions, both obese Zucker rats
[75] and obese insulin-resistant humans [6–8, 62, 66,
72, 76–80] are characterized by impaired capillary re-
cruitment as well as impaired insulin-mediated glucose
uptake by skeletal muscle in the basal state and during
hyperinsulinemia.
In accordance, accumulating evidence supports the
hypothesis that microvascular dysfunction precedes
and even predicts the development T2DM. First, a
growing number of prospective studies have shown that
microvascular dysfunction is associated with incident
impaired fasting glucose (IFG) and incident T2DM.
Recently, we analyzed and pooled thirteen [81–93] pro-
spective population-based studies in a meta-analysis
[94]. These studies focused on the microvasculature of
the skin, eye, and kidney. When all estimates of micro-
vascular dysfunction were combined, we found that, per
standard deviation (SD) greater microvascular dysfunc-
tion, the incidence of IFG increased by 15 % and the
incidence of T2DM increased by 25 %, in a follow-up
period ranging from 2.6 to 12 years. In addition, one
SD greater endothelial dysfunction, as measured with
plasma levels of endothelium-derived regulatory pro-
teins – which are likely to be derived from microvas-
cular endothelium [95] –, was associated with a 50 %
higher incidence of T2DM. Second, studies which exam-
ined diet-induced insulin resistance in both vasculature and
skeletal muscle demonstrated that microvascular endothelial
dysfunction develops well before impaired insulin activation
of PI3K in skeletal muscle [96, 97]. Third, a recent study
demonstrated reduced insulin-mediated glucose uptake by
skeletal muscle in tissue-specific knockout mice lacking
IRS-2 in endothelial cells [56]. Importantly, glucose uptake
by isolated skeletal muscle from these mice was not impaired,
indicating that microvascular endothelial dysfunction causes
impaired insulin-mediated glucose uptake even while insulin
signaling pathways in skeletal muscle cells are intact [56].
In summary, these findings strongly support the hy-
pothesis that microvascular dysfunction is a cause of
insulin resistance, by affecting insulin-mediated glucose
uptake by skeletal muscle through impaired capillary
recruitment (Fig. 2) [11–14]. Subsequently, the hyper-
glycemia and hyperinsulinemia that evolve from meta-
bolic insulin resistance can further impair endothelial
dysfunction (and thus capillary recruitment) [98–100]
and glucose disposal [18], which results in a vicious
circle (Fig. 2).
Importantly, by increasing peripheral vascular resistance,
microvascular dysfunction can also contribute to the devel-
opment of hypertension (Fig. 2), which suggests that micro-
vascular dysfunction constitutes one of the links between
insulin resistance and hypertension in the metabolic syn-
drome (reviewed elsewhere [11–14]).
4 Obesity: a cause of microvascular dysfunction
4.1 Obesity-related intracellular signaling
We [6–8] and others [9, 10, 62, 101, 102] have demonstrated
that microvascular dysfunction is impaired in obesity and
that microvascular dysfunction develops progressively
along with an increase in adipose tissue [40, 67, 103]. In
obesity, insulin-mediated activation of the PI3K pathway in
endothelial cells is selectively impaired while the insulin-
mediated activation of ERK-1/2 is intact [40, 104], i.e. there
is endothelial or microvascular insulin resistance with re-
gard to insulin’s vasodilator actions. For example, studies in
diet-induced obesity in animals revealed blunted PI3K sig-
naling pathways in endothelial cells through impaired
insulin-mediated phosphorylation of Akt [96, 105, 106]
and eNOS [56, 96, 105, 107], whereas insulin-mediated
ET-1 expression was unchanged [56, 107].
Fig. 2 Hypothesis describing microvascular dysfunction as an inter-
mediate step linking central obesity to insulin resistance (and, down-
stream, T2DM) and hypertension (adapted from Jonk [18]). TNF-α—
tumor necrosis factor-α
32 Rev Endocr Metab Disord (2013) 14:29–38
Thus, obesity-related microvascular dysfunction is charac-
terized by cellular defects in endothelial cells that influence
the balance between vasodilatation and vasoconstriction. The
selective insulin signaling impairment in endothelial
cells results in decreased NO production, which reduces
insulin-mediated nutritive capillary recruitment [39] and
trans-endothelial transport of insulin [57]. Consequently,
there is a decreased insulin-mediated glucose uptake in
skeletal muscle, i.e. skeletal muscle (i.e. metabolic) in-
sulin resistance (Fig. 2). Therefore, endothelial insulin
signaling defects play an important role in the develop-
ment of obesity-related insulin resistance.
4.2 Obesity-related endocrine signaling
The close association between adipose tissue and microvas-
cular functioning strongly suggests signaling pathways be-
tween adipose tissue and the microcirculation [11, 40].
Adipose tissue and in particular visceral adipose tissue cells
secrete a variety of bioactive substances called adipokines
[11, 40]. In obesity, there is an enhanced production of free
fatty acids (FFAs), tumor necrosis factor (TNF)-α, leptin,
resistin, and several other inflammatory cytokines [11, 40],
whereas the production of adiponectin, an anti-
inflammatory adipokine, is reduced [11, 108].
Several studies have demonstrated that systemic FFA infu-
sion inhibits insulin-mediated capillary recruitment [80,
109–111] and forearm blood flow responses [112] with sub-
sequent blunted insulin-mediated glucose uptake by skeletal
muscle [109–111, 113–117]. Conversely, lowering FFA levels
in obese subjects improved basal and insulin-mediated capil-
lary recruitment in obese insulin-resistant individuals [80].
FFA may induce insulin resistance through activation of pro-
tein kinase C (PKC) θ which subsequently inhibits insulin-
mediated phosphorylation of Akt and stimulates ERK-1/2
(Fig. 1) [118].
TNF-α inhibits both insulin-mediated capillary re-
cruitment and insulin-mediated glucose uptake by skel-
etal muscle [103, 119, 120]. TNF-α may induce
endothelial insulin resistance trough activation of intra-
cellular enzyme c-Jun N-terminal kinase (JNK) [121].
JNK has been shown to regulate both whole-body in-
sulin sensitivity and insulin-mediated cell signaling [40,
122]. Hence, activation of JNK impairs the PI3K path-
way and stimulates the phosphorylation of ERK-1/2 in
endothelial cells [121, 123], resulting in insulin-
mediated vasoconstriction (Fig. 1) [40]. Conversely, a
recent study found that specific inhibition of JNK in
db/db mice can restore the blunted insulin-mediated
vasodilatation [124].
Adiponectin has been shown to increase insulin sen-
sitivity and improve vascular function [125]. These ben-
eficial effects are probably attributable to stimulation of 5′
adenosine monophosphate-activated protein kinase
(AMPK) phosphorylation by adiponectin, which enhan-
ces insulin-mediated vasodilatation through increased
eNOS phosphorylation and decreased ERK-1/2 stimula-
tion (Fig. 1) [126, 127]. In addition, adiponectin itself
can reduce the production of proinflammatory cyto-
kines, which has favorable affects of insulin-signaling
pathways [13, 128, 129]. In obesity, adiponectin levels
are decreased, which is probably caused by TNFα and
IL-6, as well as by other inflammatory mediators [13,
129, 130].
Another important system that has been suggested to be
involved in microvascular functioning is the renin-
angiotensin system (RAS) [11]. All the components of the
RAS necessary to generate the vasoconstrictor angiotensin
II (AngII) are expressed in human adipose tissue [11, 131,
132]. In obese subjects there is enhanced activation of the
RAS, which may directly relate to the mass of adipose tissue
[11, 133]. Enhanced RAS activity may have detrimental
effects on insulin-mediated skeletal muscle glucose uptake
by 1) affecting insulin-mediated IRS-1 phosphorylation in
endothelial cells [134, 135]; 2) production of reactive oxy-
gen species (ROS), which reduce NO bioavailability [136,
137]; and 3) stimulation of the release of ET-1 [138, 139].
In addition to the above, leptin and other cytokines and
chemokines have also been implicated in the pathogenesis
of endothelial or (micro)vascular insulin resistance
(reviewed elsewhere [13, 129, 140, 141]).
In summary, in obesity, there is an increase in several
circulating adipose tissue-derived factors, in particular
FFA and TNF-α, whereas the anti-inflammatory adipo-
kine, adiponectin, is decreased. These endocrine factors
are likely candidates to influence insulin signaling path-
ways in endothelial cells, thereby causing both impaired
insulin-mediated vasodilatation and impaired skeletal
muscle glucose uptake (Fig. 1) [11]. Hence, these en-
docrine factors provide a potential link between obesity-
related microcirculatory dysfunction and obesity-related
insulin resistance (Fig. 2) [11]. In addition to these
systemic endocrine effects, we have postulated a vaso-
regulatory role for local deposits of fat next to the
microvasculature (i.e. perivascular adipose tissue, PVAT)
[11, 40, 142]. Adipokines released by these fat cells
may directly inhibit vasodilatory pathways locally, and
thus have a local rather than a systemic vasoregulatory
effect, which we named “vasocrine” [11, 40, 142]. A
recent animal study demonstrated dramatic increases in
PVAT in muscle of db/db mice. In addition, these mice
had a reduction in adiponectin release by PVAT and
decreased insulin-mediated vasodilatation [124], indicat-
ing that PVAT induces microvascular dysfunction by
influencing insulin signaling and thereby insulin’s mi-
crovascular effects [12].
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5 Conclusion
Considerable evidence exists that microvascular dysfunc-
tion is a key feature in the development of obesity-related
insulin resistance. Obesity is associated with microvascular
dysfunction through alterations in endocrine and vasocrine
signals that cause alterations in microvascular endothelial
and skeletal muscle intracellular signaling. Microvascular
dysfunction, in turn, impairs the timely access of glucose
and insulin to their target tissues, and is therefore a contrib-
utor to insulin resistance.
Therefore, the microcirculation may present a target for the
prevention and treatment of the metabolic syndrome and
T2DM [11, 12, 40]. Hence, more studies are required for
elucidation of the pathophysiological pathways that contribute
to microvascular dysfunction. Unraveling this issue may con-
tribute to more precise assessment of risk of development of
the metabolic syndrome and T2DM. In addition, unraveling
howmicrovascular dysfunction is determined and how it leads
to the metabolic syndrome and T2DM may lead to new
treatment targets as well as to a better understanding of why
certain existing treatments (i.e. angiotensin converting
enzyme- (ACE-) inhibitors, angiotensin receptor blockers
(ARBs), and physical activity) are associated with decreased
risk of developing the metabolic syndrome and T2DM.
References
1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of
obesity and trends in the distribution of body mass index among
US adults, 1999–2010. JAMA. 2012;307(5):491–7.
2. Han TS, Feskens EJ, Lean ME, Seidell JC. Associations of body
composition with type 2 diabetes mellitus. Diabet Med. 1998;15
(2):129–35.
3. Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC,
Hennekens CH. A prospective study of exercise and incidence of
diabetes among US male physicians. JAMA. 1992;268(1):63–7.
4. International Diabetes Federation (IDF). Diabetes atlas, 4th edi-
tion. Brussels: IDF; 2009.
5. Tooke JE, Goh KL. Vascular function in Type 2 diabetes mellitus
and pre-diabetes: the case for intrinsic endotheiopathy. Diabet
Med. 1999;16(9):710–5.
6. de Jongh RT, Serne EH, Ijzerman RG, de Vries G, Stehouwer
CD. Impaired microvascular function in obesity: implications for
obesity-associated microangiopathy, hypertension, and insulin
resistance. Circulation. 2004;109(21):2529–35.
7. Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serne EH,
Smulders YM, et al. Obesity is associated with impaired endothelial
function in the postprandial state. Microvasc Res. 2011;82(3):423–9.
8. Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serne EH,
Smulders YM, et al. Meal-related increases in microvascular
vasomotion are impaired in obese individuals: a potential mech-
anism in the pathogenesis of obesity-related insulin resistance.
Diabetes Care. 2011;34 Suppl 2:S342–8.
9. Agapitov AV, Correia ML, Sinkey CA, Dopp JM, Haynes WG.
Impaired skeletal muscle and skin microcirculatory function in
human obesity. J Hypertens. 2002;20(7):1401–5.
10. Keske MA, Clerk LH, Price WJ, Jahn LA, Barrett EJ. Obesity
blunts microvascular recruitment in human forearm muscle after a
mixed meal. Diabetes Care. 2009;32(9):1672–7.
11. Jonk AM, Houben AJ, de Jongh RT, Serne EH, Schaper NC,
Stehouwer CD. Microvascular dysfunction in obesity: a po-
tential mechanism in the pathogenesis of obesity-associated
insulin resistance and hypertension. Physiology (Bethesda).
2007;22:252–60.
12. De Boer MP, Meijer RI, Wijnstok NJ, Jonk AM, Houben AJ,
Stehouwer CD, et al. Microvascular dysfunction: a potential
mechanism in the pathogenesis of obesity-associated insulin re-
sistance and hypertension. Microcirculation. 2012;19(1):5–18.
13. Houben AJ, Eringa EC, Jonk AM, Serne EH, Smulders YM,
Stehouwer CD. Perivascular fat and the microcirculation: rele-
vance to insulin resistance, diabetes, and cardiovascular disease.
Curr Cardiovasc Risk Rep. 2012;6(1):80–90.
14. Levy BI, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar
ME, et al. Impaired tissue perfusion: a pathology common to
hypertension, obesity, and diabetes mellitus. Circulation.
2008;118(9):968–76.
15. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA.
Microcirculation in hypertension: a new target for treatment?
Circulation. 2001;104(6):735–40.
16. Verdant C, De Backer D. How monitoring of the microcirculation
may help us at the bedside. Curr Opin Crit Care. 2005;11(3):240–4.
17. Knotzer H, Hasibeder WR. Microcirculatory function monitoring
at the bedside–a view from the intensive care. Physiol Meas.
2007;28:R65–86.
18. Jonk AM. Microvascular actions of insulin: studies on the inter-
action with angiotensin II and on the postprandial state.
Amsterdam: GVO drukkers & vormgevers B.V., Ponsen &
Looijen; 2011.
19. Minson CT, Berry LT, Joyner MJ. Nitric oxide and neurally
mediated regulation of skin blood flow during local heating. J
Appl Physiol. 2001;91(4):1619–26.
20. Serne EH, Gans RO, ter Maaten JC, Tangelder GJ, Donker AJ,
Stehouwer CD. Impaired skin capillary recruitment in essential
hypertension is caused by both functional and structural capillary
rarefaction. Hypertension. 2001;38(2):238–42.
21. Houben AJ, Stehouwer CD. Retinal microvascular abnormalities:
can they predict future risk of hypertension? J Hypertens.
2009;27(12):2346–8.
22. Ikram MK, de Jong FJ, Vingerling JR, Witteman JC, Hofman A,
Breteler MM, et al. Are retinal arteriolar or venular diameters
associated with markers for cardiovascular disorders? The
Rotterdam study. Invest Ophthalmol Vis Sci. 2004;45:2129–34.
23. Klein R, Sharrett AR, Klein BE, Chambless LE, Cooper LS,
Hubbard LD, et al. Are retinal arteriolar abnormalities related to
atherosclerosis?: the atherosclerosis risk in communities study.
Arterioscler Thromb Vasc Biol. 2000;20:1644–50.
24. Wong TY, Islam FM, Klein R, Klein BE, Cotch MF, Castro C, et
al. Retinal vascular caliber, cardiovascular risk factors, and in-
flammation: the multi-ethnic study of atherosclerosis (MESA).
Invest Ophthalmol Vis Sci. 2006;47(6):2341–50.
25. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy:
vascular endothelial growth factor, cycoloxygenase-2 and nitric
oxide. Curr Pharm Des. 2004;10:3331–48.
26. Delles C, Michelson G, Harazny J, Oehmer S, Hilgers KF,
Schmieder RE. Impaired endothelial function of the retinal
vasculature in hypertensive patients. Stroke. 2004;35
(6):1289–93.
27. Stehouwer CD. Is measurement of endothelial dysfunction clin-
ically useful? Eur J Clin Invest. 1999;29(6):459–61.
28. Kubes P, Kerfoot SM. Leukocyte recruitment in the microcircu-
lation: the rolling paradigm revisited. News Physiol Sci.
2001;16:76–80.
34 Rev Endocr Metab Disord (2013) 14:29–38
29. Stehouwer CD. Endothelial dysfunction in diabetic nephropathy:
state of the art and potential significance for non-diabetic renal
disease. Nephrol Dial Transplant. 2004;19(4):778–81.
30. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW.
Endothelial dysfunction and pathogenesis of diabetic angiopathy.
Cardiovasc Res. 1997;34(1):55–68.
31. Kasprzak JD, Klosinska M, Drozdz J. Clinical aspects of assess-
ment of endothelial function. Pharmacol Rep. 2006;58
(Suppl):33–40.
32. Schram MT, Stehouwer CD. Endothelial dysfunction, cellular
adhesion molecules and the metabolic syndrome. Horm Metab
Res. 2005;37 Suppl 1:49–55.
33. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ,
Verma S. New markers of inflammation and endothelial cell
activation: part I. Circulation. 2003;108(16):1917–23.
34. Wolinsky H. A proposal linking clearance of circulating lipopro-
teins to tissue metabolic activity as a basis for understanding
atherogenesis. Circ Res. 1980;47:301–11.
35. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T,
Kofoed-Enevoldsen A. Albuminuria reflects widespread vas-
cular damage. The steno hypothesis. Diabetologia. 1989;32
(4):219–26.
36. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T.
Features of endothelial dysfunction in early diabetic nephropathy.
Lancet. 1989;1(8636):461–3.
37. Ochodnicky P, Henning RH, van Dokkum RP, de Zeeuw D.
Microalbuminuria and endothelial dysfunction: emerging targets
for primary prevention of end-organ damage. J Cardiovasc
Pharmacol. 2006;47 Suppl 2:S151–62. discussion S172–156.
38. Stehouwer CD, Smulders YM. Microalbuminuria and risk for
cardiovascular disease: analysis of potential mechanisms. J Am
Soc Nephrol. 2006;17:2106–11.
39. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relation-
ships between insulin resistance and endothelial dysfunction:
molecular and pathophysiological mechanisms. Circulation.
2006;113(15):1888–904.
40. Serne EH, de Jongh RT, Eringa EC, Ijzerman RG, Stehouwer CD.
Microvascular dysfunction: a potential pathophysiological role in
the metabolic syndrome. Hypertension. 2007;50(1):204–11.
41. Shulman GI. Cellular mechanisms of insulin resistance. J Clin
Invest. 2000;106(2):171–6.
42. Shulman GI. Unraveling the cellular mechanism of insulin resis-
tance in humans: new insights from magnetic resonance spectros-
copy. Physiology (Bethesda). 2004;19:183–90.
43. Hotamisligil GS. Inflammation and metabolic disorders. Nature.
2006;444(7121):860–7.
44. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabo-
lism and the pathogenesis of insulin resistance. Physiol Rev.
2007;87(2):507–20.
45. Schalkwijk CG, Stehouwer CD. Vascular complications in diabe-
tes mellitus: the role of endothelial dysfunction. Clin Sci (Lond).
2005;109(2):143–59.
46. Karlsson HK, Zierath JR. Insulin signaling and glucose transport
in insulin resistant human skeletal muscle. Cell Biochem
Biophys. 2007;48(2–3):103–13.
47. Taubes G. Insulin resistance. Prosperity’s plague. Science.
2009;325(5938):256–60.
48. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect
of insulin to stimulate skeletal muscle blood flow in obese man. A
novel mechanism for insulin resistance. J Clin Invest. 1990;85
(6):1844–52.
49. Baron AD, Steinberg H, Brechtel G, Johnson A. Skeletal muscle
blood flow independently modulates insulin-mediated glucose
uptake. Am J Physiol. 1994;266(2 Pt 1):E248–53.
50. de Haan CH, van Dielen FM, Houben AJ, de Leeuw PW, Huvers
FC, De Mey JG, et al. Peripheral blood flow and noradrenaline
responsiveness: the effect of physiological hyperinsulinemia.
Cardiovasc Res. 1997;34(1):192–8.
51. Tack CJ, Lutterman JA, Vervoort G, Thien T, Smits P. Activation
of the sodium-potassium pump contributes to insulin-induced
vasodilation in humans. Hypertension. 1996;28(3):426–32.
52. Clark MG,Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk
LH, et al. Blood flow and muscle metabolism: a focus on insulin
action. Am J Physiol Endocrinol Metab. 2003;284:E241–58.
53. Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilatation:
physiology or pharmacology? Diabetologia. 1998;41(4):369–79.
54. Zhang L, Vincent MA, Richards SM, Clerk LH, Rattigan S, Clark
MG, et al. Insulin sensitivity of muscle capillary recruitment in
vivo. Diabetes. 2004;53(2):447–53.
55. Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG,
Rattigan S, et al. Microvascular recruitment is an early insulin
effect that regulates skeletal muscle glucose uptake in vivo.
Diabetes. 2004;53(6):1418–23.
56. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H,
Takahashi T, et al. Impaired insulin signaling in endothelial cells
reduces insulin-induced glucose uptake by skeletal muscle. Cell
Metab. 2011;13(3):294–307.
57. Wang H, Wang AX, Barrett EJ. Insulin-induced endothelial cell
cortical actin filament remodeling: a requirement for trans-
endothelial insulin transport. Mol Endocrinol. 2012;26(8):1327–38.
58. Johansson GS, Chisalita SI, Arnqvist HJ. Human microvascular
endothelial cells are sensitive to IGF-I but resistant to insulin at
the receptor level. Mol Cell Endocrinol. 2008;296(1–2):58–63.
59. Rattigan S, Clark MG, Barrett EJ. Hemodynamic actions of
insulin in rat skeletal muscle: evidence for capillary recruitment.
Diabetes. 1997;46:1381–8.
60. Clark AD, Barrett EJ, Rattigan S, Wallis MG, Clark MG. Insulin
stimulates laser Doppler signal by rat muscle in vivo, consistent
with nutritive flow recruitment. Clin Sci (Lond). 2001;100
(3):283–90.
61. Vincent MA, Dawson D, Clark AD, Lindner JR, Rattigan S,
Clark MG, et al. Skeletal muscle microvascular recruitment by
physiological hyperinsulinemia precedes increases in total blood
flow. Diabetes. 2002;51(1):42–8.
62. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ.
Obesity blunts insulin-mediated microvascular recruitment in
human forearm muscle. Diabetes. 2006;55(5):1436–42.
63. Coggins M, Lindner J, Rattigan S, Jahn L, Fasy E, Kaul S, et al.
Physiologic hyperinsulinemia enhances human skeletal muscle per-
fusion by capillary recruitment. Diabetes. 2001;50(12):2682–90.
64. de Jongh RT, Clark AD, Ijzerman RG, Serne EH, de Vries G,
Stehouwer CD. Physiological hyperinsulinaemia increases intra-
muscular microvascular reactive hyperaemia and vasomotion in
healthy volunteers. Diabetologia. 2004;47(6):978–86.
65. Serne EH, Gans RO, ter Maaten JC, ter Wee PM, Donker AJ,
Stehouwer CD. Capillary recruitment is impaired in essential
hypertension and relates to insulin’s metabolic and vascular
actions. Cardiovasc Res. 2001;49(1):161–8.
66. Francischetti EA, Tibirica E, da Silva EG, Rodrigues E, Celoria
BM, de Abreu VG. Skin capillary density and microvascular
reactivity in obese subjects with and without metabolic syn-
drome. Microvasc Res. 2011;81(3):325–30.
67. Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda
JA, Donker AJ, et al. Microvascular function relates to insulin
sensitivity and blood pressure in normal subjects. Circulation.
1999;99(7):896–902.
68. Grassi G, Seravalle G, Scopelliti F, Dell’Oro R, Fattori L, Quarti-
Trevano F, et al. Structural and functional alterations of subcuta-
neous small resistance arteries in severe human obesity. Obesity
(Silver Spring). 2010;18(1):92–8.
69. Lampinen KH, Ronnback M, Groop PH, Kaaja RJ. A relationship
between insulin sensitivity and vasodilation in women with a
Rev Endocr Metab Disord (2013) 14:29–38 35
history of preeclamptic pregnancy. Hypertension. 2008;52
(2):394–401.
70. Clough GF, L’Esperance V, Turzyniecka M, Walter L,
Chipperfield AJ, Gamble J, et al. Functional dilator capacity is
independently associated with insulin sensitivity and age in cen-
tral obesity and is not improved by high dose statin treatment.
Microcirculation. 2011;18(1):74–84.
71. Vincent MA, Clerk LH, Rattigan S, Clark MG, Barrett EJ. Active
role for the vasculature in the delivery of insulin to skeletal
muscle. Clin Exp Pharmacol Physiol. 2005;32(4):302–7.
72. Serne EH, Ijzerman RG, Gans RO, Nijveldt R, De Vries G,
Evertz R, et al. Direct evidence for insulin-induced capillary
recruitment in skin of healthy subjects during physiological
hyperinsulinemia. Diabetes. 2002;51(5):1515–22.
73. Newman JM, Dwyer RM, St-Pierre P, Richards SM, Clark MG,
Rattigan S. Decreased microvascular vasomotion and myogenic
response in rat skeletal muscle in association with acute insulin
resistance. J Physiol. 2009;587(Pt 11):2579–88.
74. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S.
Inhibiting NOS blocks microvascular recruitment and blunts
muscle glucose uptake in response to insulin. Am J Physiol
Endocrinol Metab. 2003;285:E123–9.
75. Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD,
Clark MG. Insulin-mediated hemodynamic changes are impaired
in muscle of Zucker obese rats. Diabetes. 2002;51(12):3492–8.
76. Han KA, Patel Y, Lteif AA, Chisholm R, Mather KJ.
Contributions of dysglycaemia, obesity, and insulin resistance
to impaired endothelium-dependent vasodilation in humans.
Diabetes Metab Res Rev. 2011;27(4):354–61.
77. de Jongh RT, Serne EH, Ijzerman RG, Jorstad HT, Stehouwer
CD. Impaired local microvascular vasodilatory effects of insulin
and reduced skin microvascular vasomotion in obese women.
Microvasc Res. 2008;75(2):256–62.
78. Ketel IJ, Serne EH, Ijzerman RG, Korsen TJ, Twisk JW, Hompes
PG, et al. Insulin-induced capillary recruitment is impaired in
both lean and obese women with PCOS. Hum Reprod. 2011;26
(11):3130–7.
79. Ketel IJ, Stehouwer CD, Serne EH, Korsen TJ, Hompes PG,
Smulders YM, et al. Obese but not normal-weight women with
polycystic ovary syndrome are characterized by metabolic and
microvascular insulin resistance. J Clin Endocrinol Metab.
2008;93(9):3365–72.
80. de Jongh RT, Serne EH, Ijzerman RG, de Vries G, Stehouwer CD.
Free fatty acid levels modulate microvascular function: relevance
for obesity-associated insulin resistance, hypertension, and
microangiopathy. Diabetes. 2004;53(11):2873–82.
81. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE,
Gansevoort RT. Urinary albumin excretion and its relation with
C-reactive protein and the metabolic syndrome in the prediction
of type 2 diabetes. Diabetes Care. 2005;28:2525–30.
82. Friedman AN, Marrero D, Ma Y, Ackermann R, Narayan KM,
Barrett-Connor E, et al. Value of urinary albumin-to-creatinine
ratio as a predictor of type 2 diabetes in pre-diabetic individuals.
Diabetes Care. 2008;31:2344–8.
83. Ikram MK, Janssen JA, Roos AM, Rietveld I, Witteman JC,
Breteler MM, et al. Retinal vessel diameters and risk of impaired
fasting glucose or diabetes: the Rotterdam study. Diabetes.
2006;55:506–10.
84. Kifley A, Wang JJ, Cugati S, Wong TY, Mitchell P. Retinal
vascular caliber and the long-term risk of diabetes and impaired
fasting glucose: the Blue Mountains Eye Study. Microcirculation.
2008;15:373–7.
85. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka
S, Matsuzawa Y, et al. Inflammatory markers, adiponectin, and
risk of type 2 diabetes in the Pima Indian. Diabetes Care.
2003;26:1745–51.
86. Meigs JB, O’Donnell CJ, Tofler GH, Benjamin EJ, Fox CS,
Lipinska I, et al. Hemostatic markers of endothelial dysfunction
and risk of incident type 2 diabetes: the Framingham offspring
study. Diabetes. 2006;55:530–7.
87. Nguyen TT, Wang JJ, Islam FM, Mitchell P, Tapp RJ, Zimmet
PZ, et al. Retinal arteriolar narrowing predicts incidence of dia-
betes: the Australian Diabetes, Obesity and Lifestyle (AusDiab)
study. Diabetes. 2008;57:536–9.
88. Perticone F, Maio R, Sciacqua A, Andreozzi F, Iemma G,
Perticone M, et al. Endothelial dysfunction and c-reactive protein
are risk factors for diabetes in essential hypertension. Diabetes.
2008;57:167–71.
89. Sattar N, Murray HM, Welsh P, Blauw GJ, Buckley BM, de
Craen AJ, et al. Are elevated circulating intercellular adhesion
molecule 1 levels more strongly predictive of diabetes than vas-
cular risk? Outcome of a prospective study in the elderly.
Diabetologia. 2009;52:235–9.
90. Song Y, Manson JE, Tinker L, Rifai N, Cook NR, Hu FB, et al.
Circulating levels of endothelial adhesion molecules and risk of
diabetes in an ethnically diverse cohort of women. Diabetes.
2007;56:1898–904.
91. Wang Z, Hoy WE. Albuminuria as a marker of the risk of
developing type 2 diabetes in non-diabetic Aboriginal
Australians. Int J Epidemiol. 2006;35:1331–5.
92. Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper
DJ, et al. Retinal arteriolar narrowing and risk of diabetes mellitus
in middle-aged persons. JAMA. 2002;287:2528–33.
93. Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD. Retinal
arteriolar narrowing, hypertension, and subsequent risk of diabe-
tes mellitus. Arch Intern Med. 2005;165:1060–5.
94. Muris DM, Houben AJ, Schram MT, Stehouwer CD.
Microvascular dysfunction is associated with a higher incidence
of type 2 diabetes mellitus: a systematic review and meta-
analysis. Arterioscler Thromb Vasc Biol. 2012;32(12):3082–94.
95. To SS, Newman PM, Hyland VJ, Robinson BG, Schrieber L.
Regulation of adhesion molecule expression by human synovial
microvascular endothelial cells in vitro. Arthritis Rheum.
1996;39:467–77.
96. Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, et
al. Vascular inflammation, insulin resistance, and reduced nitric
oxide production precede the onset of peripheral insulin resis-
tance. Arterioscler Thromb Vasc Biol. 2008;28(11):1982–8.
97. Bonner, JS, Lantier L, Hasenour CM, James FD, Bracy DP,
Wasserman DH (2012) Muscle-specific vascular endothelial
growth factor deletion induces muscle capillary rarefaction cre-
ating muscle insulin resistance. Diabetes.
98. Chittari MV, McTernan P, Bawazeer N, Constantinides K, Ciotola
M, O’Hare JP, et al. Impact of acute hyperglycaemia on endothe-
lial function and retinal vascular reactivity in patients with Type 2
diabetes. Diabet Med. 2011;28(4):450–4.
99. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R,
Giunta R, et al. Vascular effects of acute hyperglycemia in
humans are reversed by L-arginine. Evidence for reduced avail-
ability of nitric oxide during hyperglycemia. Circulation. 1997;95
(7):1783–90.
100. Watanabe K, Oba K, Suzuki T, Ouchi M, Suzuki K, Futami-Suda
S, et al. Oral glucose loading attenuates endothelial function in
normal individual. Eur J Clin Invest. 2011;41(5):465–73.
101. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G,
Baron AD. Obesity/Insulin resistance is associated with endothe-
lial dysfunction. Implications for the syndrome of insulin resis-
tance. J Clin Invest. 1996;47(2):310–3.
102. Costa RR, Villela NR, Souza MG, Boa BC, Cyrino FZ, Silva SV,
et al. High fat diet induces central obesity, insulin resistance and
microvascular dysfunction in hamsters. Microvasc Res. 2011;82
(3):416–22.
36 Rev Endocr Metab Disord (2013) 14:29–38
103. de Jongh RT, Ijzerman RG, Serne EH, Voordouw JJ, Yudkin JS,
de Waal HA, et al. Visceral and truncal subcutaneous adipose
tissue are associated with impaired capillary recruitment in
healthy individuals. J Clin Endocrinol Metab. 2006;91
(12):5100–6.
104. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M,
et al. Characterization of selective resistance to insulin signaling
in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest.
1999;104(4):447–57.
105. Rizzo NO, Maloney E, Pham M, Luttrell I, Wessells H, Tateya S,
et al. Reduced NO-cGMP signaling contributes to vascular in-
flammation and insulin resistance induced by high-fat feeding.
Arterioscler Thromb Vasc Biol. 2010;30(4):758–65.
106. Tsuchiya K, Sakai H, Suzuki N, Iwashima F, Yoshimoto T,
Shichiri M, et al. Chronic blockade of nitric oxide synthesis
reduces adiposity and improves insulin resistance in high fat-
induced obese mice. Endocrinology. 2007;148(10):4548–56.
107. Eringa EC, Stehouwer CD, Roos MH, Westerhof N, Sipkema P.
Selective resistance to vasoactive effects of insulin in muscle
resistance arteries of obese Zucker (fa/fa) rats. Am J Physiol
Endocrinol Metab. 2007;293(5):E1134–9.
108. Arita Y, Kihara S, Ouchi N, TakahashiM,Maeda K,Miyagawa J, et
al. Paradoxical decrease of an adipose-specific protein, adiponectin,
in obesity. Biochem Biophys Res Commun. 1999;257(1):79–83.
109. Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty
acids induce insulin resistance in both cardiac and skeletal muscle
microvasculature in humans. J Clin Endocrinol Metab. 2011;96
(2):438–46.
110. Liu Z, Liu J, Jahn LA, Fowler DE, Barrett EJ. Infusing lipid raises
plasma free fatty acids and induces insulin resistance in muscle
microvasculature. J Clin Endocrinol Metab. 2009;94:3543–9.
111. Clerk LH, Rattigan S, Clark MG. Lipid infusion impairs physio-
logic insulin-mediated capillary recruitment and muscle glucose
uptake in vivo. Diabetes. 2002;51(4):1138–45.
112. Watanabe S, Tagawa T, Yamakawa K, Shimabukuro M, Ueda S.
Inhibition of the renin-angiotensin system prevents free fatty
acid-induced acute endothelial dysfunction in humans.
Arterioscler Thromb Vasc Biol. 2005;25(11):2376–80.
113. Chai W, Liu J, Jahn LA, Fowler DE, Barrett EJ, Liu Z. Salsalate
attenuates free fatty acid-induced microvascular and metabolic
insulin resistance in humans. Diabetes Care. 2011;34(7):1634–8.
114. Li H, Bao Y, Zhang X, Yu Y. Free fatty acids induce endothelial
dysfunction and activate protein kinase C and nuclear factor-
kappaB pathway in rat aorta. Int J Cardiol. 2011;152(2):218–24.
115. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron
AD. Free fatty acid elevation impairs insulin-mediated vasodila-
tion and nitric oxide production. Diabetes. 2000;49(7):1231–8.
116. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J,
Johnson A, et al. Elevated circulating free fatty acid levels impair
endothelium-dependent vasodilation. J Clin Invest. 1997;100
(5):1230–9.
117. Inyard AC, Chong DG, Klibanov AL, Barrett EJ. Muscle con-
traction, but not insulin, increases microvascular blood volume in
the presence of free fatty acid-induced insulin resistance.
Diabetes. 2009;58(11):2457–63.
118. Bakker W, Sipkema P, Stehouwer CD, Serne EH, Smulders YM,
van Hinsbergh VW, et al. Protein kinase C theta activation indu-
ces insulin-mediated constriction of muscle resistance arteries.
Diabetes. 2008;57(3):706–13.
119. Youd JM, Rattigan S, Clark MG. Acute impairment of insulin-
mediated capillary recruitment and glucose uptake in rat skeletal
muscle in vivo by TNF-alpha. Diabetes. 2000;49(11):1904–9.
120. Zhang L, Wheatley CM, Richards SM, Barrett EJ, Clark MG,
Rattigan S. TNF-alpha acutely inhibits vascular effects of phys-
iological but not high insulin or contraction. Am J Physiol
Endocrinol Metab. 2003;285(3):E654–60.
121. Eringa EC, Stehouwer CD, Walburg K, Clark AD, van
Nieuw Amerongen GP, Westerhof N, et al. Physiological
concentrations of insulin induce endothelin-dependent vaso-
constriction of skeletal muscle resistance arteries in the pres-
ence of tumor necrosis factor-alpha dependence on c-Jun N-
terminal kinase. Arterioscler Thromb Vasc Biol. 2006;26
(2):274–80.
122. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda
K, et al. A central role for JNK in obesity and insulin resistance.
Nature. 2002;420(6913):333–6.
123. Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. Tumor necrosis
factor-alpha induces insulin resistance in endothelial cells via a
p38 mitogen-activated protein kinase-dependent pathway.
Endocrinology. 2007;148(7):3356–63.
124. Meijer RI, Bakker W, Alta CL, Sipkema P, Yudkin JS, Viollet B,
et al. (2012). Perivascular adipose tissue control of insulin-
induced vasoreactivity in muscle is impaired in db/db Mice.
Diabetes.
125. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H.
Serum concentrations of adiponectin and risk of type 2 diabetes
mellitus and coronary heart disease in apparently healthy middle-
aged men: results from the 18-year follow-up of a large cohort from
southern Germany. J Am Coll Cardiol. 2006;48(7):1369–77.
126. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ.
Adiponectin stimulates production of nitric oxide in vascular
endothelial cells. J Biol Chem. 2003;278(45):45021–6.
127. Zheng Q, Yuan Y, Yi W, Lau WB, Wang Y, Wang X, et al. C1q/
TNF-related proteins, a family of novel adipokines, induce vas-
cular relaxation through the adiponectin receptor-1/AMPK/
eNOS/nitric oxide signaling pathway. Arterioscler Thromb Vasc
Biol. 2011;31(11):2616–23.
128. Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT, et al.
Macrophage adiponectin expression improves insulin sensitivity
and protects against inflammation and atherosclerosis. Diabetes.
2010;59(4):791–9.
129. Meijer RI, Serne EH, Smulders YM, van Hinsbergh VW, Yudkin
JS, Eringa EC. Perivascular adipose tissue and its role in type 2
diabetes and cardiovascular disease. Curr Diab Rep. 2011;11
(3):211–7.
130. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose
tissue, inflammation and immunity. Nat Rev Immunol. 2006;6
(10):772–83.
131. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B,
Carlsson LM. Human adipose tissue expresses angiotensinogen
and enzymes required for its conversion to angiotensin II. J Clin
Endocrinol Metab. 1998;83(11):3925–9.
132. Schling P, Mallow H, Trindl A, Loffler G. Evidence for a local
renin angiotensin system in primary cultured human preadipo-
cytes. Int J Obes Relat Metab Disord. 1999;23(4):336–41.
133. Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adipose
depot-specific modulation of angiotensinogen gene expression
in diet-induced obesity. Am J Physiol Endocrinol Metab.
2004;286(6):E891–5.
134. Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G.
Angiotensin II impairs the insulin signaling pathway promoting
production of nitric oxide by inducing phosphorylation of insulin
receptor substrate-1 on Ser312 and Ser616 in human umbilical
vein endothelial cells. Circ Res. 2004;94(9):1211–8.
135. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR.
Cross-talk between the insulin and angiotensin signaling systems.
Proc Natl Acad Sci U S A. 1996;93(22):12490–5.
136. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA,
Griendling KK, et al. Angiotensin II-mediated hypertension in
the rat increases vascular superoxide production via membrane
NADH/NADPH oxidase activation. Contribution to alterations of
vasomotor tone. J Clin Invest. 1996;97(8):1916–23.
Rev Endocr Metab Disord (2013) 14:29–38 37
137. Zhou MS, Schulman IH, Raij L. Role of angiotensin II and
oxidative stress in vascular insulin resistance linked to hyperten-
sion. Am J Physiol Heart Circ Physiol. 2009;296(3):H833–9.
138. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG, et al.
Angiotensin II induces endothelin-1 gene expression via extra-
cellular signal-regulated kinase pathway in rat aortic smooth
muscle cells. Cardiovasc Res. 2004;61(1):159–68.
139. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F.
Induction of endothelin-1 gene by angiotensin and vasopressin in
endothelial cells. Hypertension. 1992;19(6 Pt 2):753–7.
140. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW.
Endothelial dysfunction and diabetes: roles of hyperglycemia,
impaired insulin signaling and obesity. Cell Tissue Res.
2009;335(1):165–89.
141. Eringa EC, Bakker W, van Hinsbergh VW. Paracrine regulation
of vascular tone, inflammation and insulin sensitivity by perivas-
cular adipose tissue. Vascul Pharmacol. 2012;56(5–6):204–9.
142. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from
perivascular fat: a mechanism linking insulin resistance to vascu-
lar disease. Lancet. 2005;365(9473):1817–20.
38 Rev Endocr Metab Disord (2013) 14:29–38
